Robert L. Coleman

1994–2026 年に発表

別表記
Robert L Coleman
257
論文数
44,230
被引用数
107
h 指数
248
i10 指数

被引用数

Robert L. Coleman の年別被引用数1974 年: 被引用 1 件1994 年: 被引用 2 件1996 年: 被引用 3 件1997 年: 被引用 4 件1998 年: 被引用 10 件1999 年: 被引用 9 件2000 年: 被引用 11 件2001 年: 被引用 15 件2002 年: 被引用 15 件2003 年: 被引用 31 件2004 年: 被引用 29 件2005 年: 被引用 33 件2006 年: 被引用 50 件2007 年: 被引用 77 件2008 年: 被引用 156 件2009 年: 被引用 162 件2010 年: 被引用 205 件2011 年: 被引用 267 件2012 年: 被引用 267 件2013 年: 被引用 238 件2014 年: 被引用 318 件2015 年: 被引用 274 件2016 年: 被引用 340 件2017 年: 被引用 398 件2018 年: 被引用 367 件2019 年: 被引用 1,505 件2020 年: 被引用 1,933 件2021 年: 被引用 1,782 件2022 年: 被引用 1,721 件2023 年: 被引用 1,453 件2024 年: 被引用 2,344 件2025 年: 被引用 1,087 件2026 年: 被引用 23 件1975〜1993 年は被引用が無いため表示していません1995 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 4,383 件、この内訳の 23.4%中国: 引用元論文 2,311 件、この内訳の 12.4%イタリア: 引用元論文 1,203 件、この内訳の 6.4%イギリス: 引用元論文 1,154 件、この内訳の 6.2%ドイツ: 引用元論文 777 件、この内訳の 4.2%カナダ: 引用元論文 744 件、この内訳の 4%フランス: 引用元論文 730 件、この内訳の 3.9%スペイン: 引用元論文 606 件、この内訳の 3.2%日本: 引用元論文 532 件、この内訳の 2.8%オーストラリア: 引用元論文 521 件、この内訳の 2.8%オランダ: 引用元論文 404 件、この内訳の 2.2%韓国: 引用元論文 401 件、この内訳の 2.1%
0%23.4%その他 26.4%

分野

  • Medicine61.9%
  • Biochemistry, Genetics and Molecular Biology29.6%
  • Immunology and Microbiology2.5%
  • Materials Science1.1%
  • Neuroscience1.1%
  • Engineering1%
  • その他2.8%

トピック

  • Ovarian cancer diagnosis and treatment7.4%
  • PARP inhibition in cancer therapy5.6%
  • Endometrial and Cervical Cancer Treatments4.7%
  • MicroRNA in disease regulation2%
  • Breast Cancer Treatment Studies2%
  • HER2/EGFR in Cancer Research2%
  • その他76.3%

共著者

全論文

検索で開く
  1. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Matthew A. Powell - New England Journal of Medicine 2023 被引用: 800

  2. Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook

    著者: , , , , , , - Cancer Treatment Reviews 2020 被引用: 1,136

  3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , James Sun, Kevin Lin, Heidi Giordano, Jonathan A. Ledermann, Martin Buck, Andrew Dean, Michael Friedländer, Jeffrey C. Goh, Paul R. Harnett, Ganessan Kichenadasse, Clare L. Scott, Hannelore Denys, Luc Dirix, Ignace Vergote, Laurie Elit, Prafull Ghatage, Amit M. Oza, Marie Plante, Diane Provencher, Johanne I. Weberpals, Stephen Welch, Anne Floquet, Laurence Gladieff, Florence Joly, Alexandra Léary, Alain Lortholary, Jean‐Pierre Lotz, Jacques Médioni, Olivier Trédan, Benoît You, Ayşe Balat, Claudia Hänle, Petra Krabisch, Tanja Neunhöffer, Martin Pölcher, Pauline Wimberger, A Amit, Svetlana Kovel, Michelle Leviov, Tamar Safra, Ronnie Shapira‐Frommer, Salomon M. Stemmer, Alessandra Bologna, Nicoletta Colombo, Domenica Lorusso, Sandro Pignata, Roberto Sabbatini, Giovanni Scambia, Stefano Tamberi, Claudio Zamagni, Peter C.C. Fong, Anne O’Donnell, Margarita Amenedo, A. Casado Herráez, Jesús García-Donás, E.M. Guerra, Ana Oaknin, Isabel Palacio, Ignacio Romero, A Sanchez, Susana Banerjee, Andrew R. Clamp, Yvette Drew, Hani Gabra, D Jackson, JA Ledermann, Iain A. McNeish, C. A. Parkinson, Melanie Powell, Carol Aghajanian ほか 17 名 - The Lancet 2017 被引用: 1,704

  4. Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study

    著者: , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2023 被引用: 372

  5. Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

    著者: , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 被引用: 1,869

  6. Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Dowsett, Frances Duane, Vaughan Evans, Marianne Ewertz, Bernard Fisher, John Forbes, Leslie G. Ford, J.-C. Gazet, Richard D. Gelber, Lucy Gettins, Luca Gianni, Michael Gnant, Jon Godwin, Aron Goldhirsch, Pamela J. Goodwin, Richard Gray, Daniel F. Hayes, Catherine Hill, James N. Ingle, Reshma Jagsi, R. Jakesz, Sam James, Wolfgang Janni, Hui Liu, Zulian Liu, Caroline Lohrisch, Sibylle Loibl, Liz MacKinnon, Andreas Makris, Eleftherios P. Mamounas, Gurdeep Mannu, Miguel Martín, S. Mathoulin, L. Mauriac, Paul McGale, Theresa McHugh, Philip Morris, Hirofumi Mukai, Larry Norton, Yasuo Ohashi, Ivo A. Olivotto, Soon Young Paik, Hongchao Pan, Richárd Pető, Martine Piccart, Lori J. Pierce, Philip Poortmans, Trevor J. Powles, K.I. Pritchard, Joseph Ragaz, Vinod Raina, Peter M. Ravdin, Simon Read, Meredith M. Regan, J.F.R. Robertson, Emiel J. Rutgers, Suzy Scholl, Dennis J. Slamon, Lidija Sölkner, Joseph A. Sparano, Seth M. Steinberg, Rosemary Sutcliffe, Sandra M. Swain, Carolyn Taylor, Andrew Tutt, Pinuccia Valagussa, Cornelis J.�H. van de Velde, Jos A. van der Hage, Giuseppe Viale, Gϋnter von Minckwitz ほか 10 名 - The Lancet Oncology 2017 被引用: 1,133

  7. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Frederik Marmé, Shannon N. Westin, Iain A. McNeish, Danny Shih, Kevin K. Lin, Sandra Goble, Stephanie Hume, Keiichi Fujiwara, Rebecca Kristeleit - Journal of Clinical Oncology 2022 被引用: 384

  8. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Nature Medicine 2006 被引用: 1,296

  9. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Ugo De Giorgi, Maria Bjurberg, Michael A. Gold, David M. O’Malley, Brigitte Honhon, Christof Vulsteke, Eveline Cuypere, Hannelore Denys, Jean‐François Baurain, Claudio Zamagni, Meaghan Tenney, Mary E. Gordinier, William H. Bradley, Matthew Schlumbrecht, Nicola M. Spirtos, Nicole Concin, Sven Mahner, Giovanni Scambia, Charles A. Leath, Robin Farias‐Eisner, Joshua M. Cohen, Carolyn Muller, Sumeet Bhatia - The Lancet Oncology 2021 被引用: 394

  10. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carol Aghajanian, Michael A. Bookman - New England Journal of Medicine 2019 被引用: 929

  11. Exploring and comparing adverse events between PARP inhibitors

    著者: , , , - The Lancet Oncology 2019 被引用: 479

  12. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Iain A. McNeish - The Lancet Oncology 2016 被引用: 1,200

  13. BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , - Cancer Discovery 2018 被引用: 432

  14. Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , - The Lancet 2022 被引用: 222

  15. openalex_id:w4226022025

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , 被引用: 180

  16. Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    著者: , , , , , , , , , , , , , , , , , , - The Lancet Oncology 2017 被引用: 602

  17. Final Overall Survival of a Randomized Trial of Bevacizumab for Primary Treatment of Ovarian Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2019 被引用: 483

  18. Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Barbara Ruepp, Angelo Di Leo, Alan S. Coates, Richard D. Gelber, Aron Goldhirsch, Meredith M. Regan - New England Journal of Medicine 2018 被引用: 673

  19. The forefront of ovarian cancer therapy: update on PARP inhibitors

    著者: , , , , , , - Annals of Oncology 2020 被引用: 370

  20. Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mitch Raponi, Iain A. McNeish, Elizabeth M. Swisher, Kevin Lin, Clare L. Scott - Cancer Discovery 2017 被引用: 417

  21. ConCerv: a prospective trial of conservative surgery for low-risk early-stage cervical cancer

    著者: , , , , , , , , , , , , , , , , , , , , , - International Journal of Gynecological Cancer 2021 被引用: 230

  22. Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alexander Dobrovic, Clare L. Scott, Kevin Lin, Iain A. McNeish - Nature Communications 2021 被引用: 205

  23. RNA interference in the clinic: challenges and future directions

    著者: , , , , - Nature reviews. Cancer 2010 被引用: 814

  24. MILO/ENGOT-ov11: Binimetinib Versus Physician’s Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum

    著者: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 被引用: 153